How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,087 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Innate Neutrophilic Nasal Inflammation in a Pollen Exposure Chamber

have a negative urine pregnancy test at Visit 1. All females of child bearing potential must agree to a medically acceptable form of birth control throughout the study duration and for at least 1 month prior to Visit 1. Acceptable methods of birth control for this study include: oral, patch, or intra-vaginal contraceptives Norplant System® Depo-Provera® Intrauterine device (IUD) double barrier method abstinence surgically sterile females (hysterectomy or tubal ligation) > 1 year post-menopausal

2018 Clinical Trials

62. Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

-HCG) at screening and urine pregnancy at baseline. Female subjects of childbearing potential must be willing to use an acceptable form of birth control from the day of the first dose administration to 30 days after the last administration of IP. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (Medroxyprogesterone acetate-stabilized for at least 3 months); vaginal contraceptive

2018 Clinical Trials

63. Equivalence Study to Compare Two Strengths of Creon in China

days immediately after the last dose of study drug. Medically acceptable methods of birth control include bilateral tubal ligation or the use of either a contraceptive implant, a contraceptive injection (e.g. Depo-Provera™), an intrauterine device, or an oral contraceptive taken within the past three months where the subject agrees to continue using during the study or to adopt another birth control method, or a double-barrier method which consists of a combination of any two of the following

2018 Clinical Trials

64. A Study to Evaluate the Efficacy of the Investigational Products on Complete Spontaneous Bowel Movements in Participants Who Normally Have ≤ 3 Complete Spontaneous Bowel Movements Per Week But Are Otherwise Healthy

control and have a negative urine pregnancy test result. All birth control must have been in use for a minimum of three months and the participant must have one regular menstrual cycle in the last 30 days. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method

2018 Clinical Trials

65. A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne

adequate contraception (e.g., total abstinence, intrauterine device (IUD), barrier method with spermicide, surgical sterilization or surgically sterilized partner, Depo-Provera®, Norplant®, or NuvaRing® for the duration of the Screening Period and during study participation. All oral contraceptive and hormonal implants will need to have been initiated and on a stable dose for at least 3 months prior to the screening period. Women of childbearing potential are defined as any female who has experienced

2018 Clinical Trials

66. Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

contraception. If hormonal contraception has been used, the following applies: If recently used intramuscular Depo-Provera must have had last injection at least 3 months prior enrollment; If using an IUD or an implant, she is planning to have this removed for purposes unrelated to enrollment in the study prior to entering the efficacy phase; Completion of her last pack of oral contraceptives or completion of effectiveness period for a monthly injection, patch or ring if any has been used prior to entering

2018 Clinical Trials

67. Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

into the study, females of childbearing potential (premenopausal women who are not permanently sterilized by means of hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) must commit to consistent and correct use of a highly effective method of birth control (true sexual abstinence, a vasectomized sexual partner, Implanon, female tubal occlusion, Intrauterine device (IUD), Depo provera injections, oral contraceptive pills or Nuvaring) for the duration of the trial and for 3 months after the last

2018 Clinical Trials

68. Benralizumab for Eosinophilic Gastritis

include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective IUD intrauterine device/IUS levonogestrel Intrauterine system, Depo-Provera(tm) injections, oral contraceptive, and Evra Patch(tm) or Nuvaring(tm). WOCBP must agree to use effective method of birth control, as defined above, from enrollment, throughout the study duration and within 16 weeks after last dose of IP, and have negative serum pregnancy test result on Visit 0

2018 Clinical Trials

69. UCSF College Health Study on Contraceptive Training and Education at Community Colleges

student knows these reversible methods including male condom, female condom, oral contraceptive pill, transdermal patch, vaginal ring, Depo-provera injectable, intrauterine device, subdermal implant, and emergency contraception. Secondary Outcome Measures : Change in student access to contraceptive services over 12 months, measured as whether student knows of or visited health services for contraceptives (questionnaire) [ Time Frame: Baseline, 12 months ] Change in willingness to use long-acting (...) contraceptive pill, transdermal patch, vaginal ring, Depo-provera injectable, intrauterine device, subdermal implant, and emergency contraception. The researchers will assess the outcome of student contraceptive knowledge by sociodemographic factors (age, race/ethnicity, parental education, health insurance, receipt of public assistance) and reproductive characteristics (parity, pregnancy intentions, male partner, prior contraceptive use). Sub-analyses for change in student access to contraceptive services

2018 Clinical Trials

70. A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea

-uterine devices (IUD), or using hormonal implants (e.g., Norplant) or injections (e.g., Depo-Provera) for contraception or used within the past 6 months; Patient is currently using an oral contraceptive for less than 3 months, has been on a unstable dose within the last 3 months or has switched from one oral contraceptive to another within the last 3 months or intends to do so in the course of the study; Patient has a history of chronic abuse of alcohol (regularly consumes 3 or more alcoholic drinks

2018 Clinical Trials

71. Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

. Administration of glucagon within 14 days of Screening. Pregnant and/or Lactating. For subjects of childbearing potential, there is a requirement for a negative urine pregnancy test and for agreement to use contraception and to refrain from breast feeding during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an intra-uterine device, the double barrier method (the female uses a diaphragm

2018 Clinical Trials

72. Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI

methods of birth control: abstinence, oral contraceptive, Norplant, Depo-Provera, a condom with spermicide, a cervical cap with spermicide, a diaphragm with spermicide, an intrauterine device, surgical sterilization (having your tubes tied) Able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments Individuals who meet the study criteria but have impaired decision making capacity may participate provided

2018 Clinical Trials

73. India Dexamethasone and Betamethasone

alcoholic consumption during the study duration. - Absence of disease markers of HIV I and 2, Hepatitis Band C and Syphilis. - Female subjects of childbearing potential must be using two acceptable methods of contraception, ( e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, progestin only implants and long acting injectables (Depo Provera), etc.). These measures are required during the study and for at least two weeks after the last dose and conveyed

2018 Clinical Trials

74. Safety and Efficacy of Albuterol Administered by the Halixâ„¢ Dry Powder Inhaler in Subjects With Asthma

, double barrier method, oral/implantable/transdermal contraception, Depo-Provera, intrauterine device, having one male sexual partner who has undergone vasectomy); a woman is of CBP unless she is premenarchal, is at least 2 years postmenopausal, is without a uterus and/or both ovaries, has had a bilateral tubal ligation, or has undergone the Essure procedure with confirmation of tubal blockage. [Note: If a female is identified as less than 2 years postmenopausal, a serum follicle-stimulating hormone

2018 Clinical Trials

75. A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

implants, progesterone releasing intrauterine devices [IUDs], vaginal ring, and postcoital contraceptive methods) and hormone replacement therapy must have been discontinued at least 28 days prior to the first dose of investigational product. Use of hormone based intravaginal creams (i.e., Estrace) for treatment of vaginal dryness, itching, or burning due to menopause and/or vulvovaginal atrophy Depo Provera must have been discontinued at least 6 months prior to the first dose of investigational

2018 Clinical Trials

76. Hormonal Contraceptive Methods on Immunologic Changes in the Female Genital Tract (FGT) and Systemically

(DMPA) as contraception. Drug: Depot medroxyprogesterone acetate (DMPA) Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks Other Names: Medroxyprogesterone acetate (MPA) Depo-Provera Etonogestrel implant (Eng-Implant) This arm includes subjects that choose Etonogestrel implant (Eng-Implant

2018 Clinical Trials

77. Prevalence and factors influencing modern contraceptive use among HIV-positive women in Kilimanjaro region, northern Tanzania Full Text available with Trip Pro

-positive women attending Care and Treatment Clinics (CTC) in the selected districts. Multivariate logistic regression analysis was used to determine independent predictors of modern contraceptive use.In total 672 HIV-positive women were enrolled. Their mean age was 36.4 years (±7.7). Fifty four percent (362) were currently using modern contraceptives, and the most common method used was male condoms 76% (275) followed by Depo-Provera 28% (101). A total of 33% (121) of the users reported dual

2018 Contraception and Reproductive Medicine

78. Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

(excluding women who are surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control from the day of the first dose administration to 30 days after the last administration of study drug. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (stabilized for at least 3 months

2018 Clinical Trials

79. Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD

of contraception include oral contraceptives, barrier with spermicide, IUD, levonorgestrel implant (Norplant ®), medroxyprogesterone acetate (Depo Provera ®), surgical sterilization, contraceptive patch, vaginal contraceptive ring, and complete abstinence (not having sex)); able to provide at least 2 locators; able to provide voluntary informed consent. Exclusion Criteria: Current alcohol withdrawal (AW), evidenced by CIWA-Ar scale > 7 Severe psychiatric conditions, including past or current DSM-5 diagnosis

2018 Clinical Trials

80. GABA Pathways in Autism Spectrum Disorder (ASD)

), medroxyprogesterone injections (e.g. Depo-Provera), etonogestrel implants (e.g., Implanon, Norplan), normal and low dose combined oral contraceptive pills, norelgestromin / EE transdermal system, intravaginal device (e.g., EE and etonogestrel) and desogestrel (Cerazette). Pregnancy or breastfeeding (is a routine exclusion for research MRI scanning). Female study participants must be willing to use one form of highly effective non-hormonal contraception for one week after study drug administration. This would

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>